We are live on
!
Find out more
PCM
Perkins Capital Management Portfolio holdings
AUM
$133M
1-Year Est. Return
127.86%
This Fund
S&P 500
This Quarter
Est. Return
+9.51%
1 Year Est. Return
+127.86%
3 Year Est. Return
+303.11%
5 Year Est. Return
+333.48%
10 Year Est. Return
–
AUM
$94.7M
AUM Growth
+$5.36M
(+6%)
Cap. Flow
+$2.1M
Cap. Flow
% of AUM
2.21%
Top 10 Holdings %
Top 10 Hldgs %
35.56%
Holding
109
New
5
Increased
19
Reduced
37
Closed
9
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AUGX
Augmedix, Inc. Common Stock
AUGX
|
+$1.57M |
| 2 |
SKYT
SkyWater Technology
SKYT
|
+$1.18M |
| 3 |
8x8 Inc
EGHT
|
+$838K |
| 4 |
Usio Inc
USIO
|
+$566K |
| 5 |
Elutia
ELUT
|
+$255K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CareDx
CDNA
|
+$969K |
| 2 |
UPH
UpHealth, Inc.
UPH
|
+$415K |
| 3 |
CSII
Cardiovascular Systems, Inc.
CSII
|
+$335K |
| 4 |
RingCentral
RNG
|
+$221K |
| 5 |
QUMU
Qumu Corp.
QUMU
|
+$148K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 57.13% |
| 2 | Technology | 22.19% |
| 3 | Communication Services | 7.13% |
| 4 | Industrials | 6.74% |
| 5 | Consumer Staples | 4.38% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Eli Lilly
LLY
$1.05T
| $4.83M | 5.1% |
13,216
| – | – |
|
2
Idexx Laboratories
IDXX
$43.7B
| $4.41M | 4.65% |
10,805
| – | – |
|
3
Digi International
DGII
$2.88B
| $3.98M | 4.2% |
108,883
-1,550
| -1% | -$59.7K |
|
4
Microsoft
MSFT
$3.81T
| $3.67M | 3.88% |
15,326
| – | – |
|
5
Axogen
AXGN
$2.77B
| $3.06M | 3.23% |
307,040
+400
| +0.1% | +$4.44K |
|
6
Veracyte
VCYT
$3.48B
| $2.92M | 3.08% |
123,030
-500
| -0.4% | -$11.6K |
|
7
Abbott
ABT
$195B
| $2.91M | 3.07% |
26,480
-500
| -2% | -$51.8K |
|
8
Perion Network
PERI
$382M
| $2.7M | 2.85% |
106,571
-150
| -0.1% | -$3.65K |
|
|
AUGX
9
DELISTED
Augmedix, Inc. Common Stock
AUGX
| $2.62M | 2.77% |
1,680,428
+1,233,528
| +276% | +$1.57M |
|
10
Pfizer
PFE
$159B
| $2.58M | 2.73% |
50,416
-800
| -2% | -$38.4K |
|
11
Natera
NTRA
$47B
| $2.49M | 2.63% |
61,900
-150
| -0.2% | -$6.18K |
|
|
STRM
12
DELISTED
Streamline Health Solutions
STRM
| $2.47M | 2.6% |
104,095
-4,014
| -4% | -$97.7K |
|
13
Alphatec Holdings
ATEC
$1.46B
| $2.26M | 2.38% |
182,717
-1,000
| -0.5% | -$10.1K |
|
14
TELA Bio
TELA
$31.4M
| $1.99M | 2.1% |
173,250
-500
| -0.3% | -$4.48K |
|
15
Ooma
OOMA
$629M
| $1.98M | 2.09% |
145,400
-650
| -0.4% | -$9.62K |
|
16
AbbVie
ABBV
$451B
| $1.88M | 1.98% |
11,608
| – | – |
|
17
NeoGenomics
NEO
$2.32B
| $1.83M | 1.93% |
197,700
+2,150
| +1% | +$20K |
|
18
LeMaitre Vascular
LMAT
$1.84B
| $1.73M | 1.83% |
37,586
-1,314
| -3% | -$61.5K |
|
19
OptimizeRx
OPRX
$150M
| $1.71M | 1.81% |
101,763
+200
| +0.2% | +$3.46K |
|
20
General Mills
GIS
$22.2B
| $1.7M | 1.8% |
20,325
| – | – |
|
21
Advanced Micro Devices
AMD
$760B
| $1.66M | 1.76% |
25,684
| – | – |
|
|
PFIE
22
DELISTED
Profire Energy, Inc
PFIE
| $1.52M | 1.6% |
1,429,830
-23,685
| -2% | -$24.1K |
|
23
AtriCure
ATRC
$2.47B
| $1.48M | 1.56% |
33,350
-1,000
| -3% | -$41.8K |
|
24
Magnite
MGNI
$3.4B
| $1.44M | 1.52% |
136,075
| – | – |
|
25
Merck
MRK
$366B
| $1.32M | 1.4% |
11,925
| – | – |
|
Similar funds
AA
WA
AC
BCVI
SWM
HAP
RHIG
CWM
Perkins Capital Management's Q4 2022 Portfolio in Review
As of Q4 2022, Perkins Capital Management held 109 positions worth $94.7M, up 6% from $89.4M the previous quarter. Its ten largest holdings account for 36% of the portfolio.
Perkins Capital Management's Q4 2022 filing shows 5 new, 19 increased, 37 reduced and 9 closed positions. Its largest new stake was SkyWater Technology: 140,000 shares worth $995K. The largest sale was CareDx, an estimated $969K.
By sector, the portfolio is most concentrated in Healthcare at 57% of assets, down from 58% a quarter earlier, followed by Technology and Communication Services.
- Perkins Capital Management's largest Q4 2022 buy was SkyWater Technology: 140,000 shares worth $995K.
- Perkins Capital Management added most to Augmedix, Inc. Common Stock in Q4 2022, an estimated $1.57M increase.
- Perkins Capital Management's biggest Q4 2022 reduction was Biolase, Inc., cutting an estimated $124K.
- Perkins Capital Management fully exited CareDx in Q4 2022, selling an estimated $969K.
- Perkins Capital Management's ten largest holdings make up 36% of its $94.7M portfolio in Q4 2022.
- Perkins Capital Management opened 5 new positions and closed 9 in Q4 2022.
- Perkins Capital Management's portfolio value rose 6% quarter-over-quarter to $94.7M.
Based on Perkins Capital Management's 13F filing for Q4 2022, filed 26 Jan 2023.